{"id":"NCT02226120","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction","officialTitle":"A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-16","primaryCompletion":"2017-12-28","completion":"2017-12-28","firstPosted":"2014-08-27","resultsPosted":"2019-02-20","lastUpdate":"2019-02-20"},"enrollment":1980,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Heart Failure With Reduced Ejection Fraction"],"interventions":[{"type":"DRUG","name":"LCZ696","otherNames":[]}],"arms":[{"label":"LCZ696","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to collect safety and tolerability data on LCZ696 in eligible PARADIGM-HF patients who received open-label investigational drug. The parent PARADIGM-HF (NCT01035255) trial was terminated early due to compelling efficacy of LCZ696 in patients with heart failure with reduced ejection fraction (HFrEF) after the final pre-specified interim analysis in March 2014.","primaryOutcome":{"measure":"Percentage of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs) and Deaths as a Measure of Safety and Tolerability of LCZ696","timeFrame":"From first dose of study treatment to 30 days after last dose of study treatment, up to 30 months.","effectByArm":[{"arm":"LCZ696","deltaMin":1289,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":394,"countries":["United States","Argentina","Belgium","Brazil","Bulgaria","Canada","Chile","Czechia","Denmark","Estonia","Finland","France","Germany","Guatemala","Hong Kong","Hungary","India","Israel","Italy","Latvia","Lithuania","Malaysia","Mexico","Netherlands","Panama","Peru","Philippines","Poland","Portugal","Romania","Russia","Singapore","Slovakia","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":555,"n":1980},"commonTop":["Hypotension","Hyperkalaemia"]}}